2025年5月30日-6月3日，美国临床肿瘤学会（ASCO）年会将于美国芝加哥举行。近日，ASCO官网公布摘要题目及讲者信息。【肿瘤资讯】特别整理全体大会（Plenary Session）、口头摘要专场（Oral Abstract Session）、口头摘要速递专场（Rapid Oral Abstract Session）、临床科学研讨会（Clinical Science Symposium）的泌尿生殖系统肿瘤重磅研究，以飨读者。
口头摘要专场
（Oral Abstract Session）
摘要号：4500
英文标题：Nivolumab plus ipilimumab (NIVO+IPI) vs gemcitabine-carboplatin (gem-carbo) chemotherapy for previously untreated unresectable or metastatic urothelial carcinoma (mUC): Final results for cisplatin-ineligible patients from the CheckMate 901 trial
中文标题：纳武利尤单抗联合伊匹木单抗（NIVO+IPI）对比吉西他滨-卡铂（gem-carbo）化疗用于既往未经治疗的不可切除或转移性尿路上皮癌（mUC）：CheckMate 901研究中对顺铂不耐受患者的最终结果
讲者：Michiel Simon Van Der Heijden, MD, PhD | Netherlands Cancer Institute
摘要号：4501
英文标题：Avelumab + sacituzumab govitecan (SG) vs avelumab monotherapy as first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC): Interim analysis from the JAVELIN Bladder Medley phase 2 trial
中文标题：Avelumab联合Sacituzumab Govitecan（SG）对比Avelumab单药治疗作为晚期尿路上皮癌（aUC）患者的一线（1L）维持治疗：JAVELIN Bladder Medley 2期试验的中期分析
讲者：Jeannie Hoffman-Censits, MD | The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Greenberg Bladder Cancer Institute
摘要号：4502
英文标题：Exploratory analysis of responders from the phase 3 EV-302 trial of enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC)
中文标题：对EV-302 3期试验中接受 enfortumab vedotin联合帕博利珠单抗（EV+P）对比化疗（chemo）治疗的既往未经治疗的局部晚期或转移性尿路上皮癌（la/mUC）缓解患者进行的探索性分析
讲者：Shilpa Gupta, MD | Cleveland Clinic Taussig Cancer Institute
摘要号：4503
英文标题：Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA
中文标题：在NIAGARA研究中接受围手术期度伐利尤单抗（D）治疗的肌层浸润性膀胱癌（MIBC）患者的循环肿瘤DNA（ctDNA）
讲者：Thomas Powles, MD, PhD, FCRP | Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomew’s Hospital
摘要号：LBA4504
英文标题：Mitomycin plus BCG as adjuvant intravesical therapy for high-risk, non–muscle-invasive bladder cancer: A randomized phase 3 trial (ANZUP 1301)
中文标题：丝裂霉素联合卡介苗作为高危非肌层浸润性膀胱癌的辅助膀胱内治疗：一项随机3期试验（ANZUP 1301）
讲者：Dickon Hayne, MD, FRCS, MBBS | UWA Medical School, University of Western Australia
摘要号：4505
英文标题：Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis from the phase 3 CheckMate 214 trial
中文标题：纳武利尤单抗联合伊匹木单抗对比舒尼替尼用于晚期肾细胞癌的一线治疗：来自3期CheckMate 214试验的最终分析
讲者：Robert J. Motzer, MD | Memorial Sloan Kettering Cancer Center
摘要号：4506
英文标题：Combination casdatifan plus cabozantinib expansion cohort of phase 1 ARC-20 study in previously treated patients with clear cell renal cell carcinoma
中文标题：卡博替尼联合combination casdatifan扩展队列在既往接受过治疗的透明细胞肾细胞癌患者中的1期ARC-20研究
讲者：Toni K. Choueiri, MD, FASCO | Department of Medical Oncology, Dana-Farber Cancer Institute
摘要号：4507
英文标题：Hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan in von Hippel-Lindau (VHL) disease–associated neoplasms: 5-year follow-up of the phase 2 LITESPARK-004 study
中文标题：低氧诱导因子-2α（HIF-2α）抑制剂贝组替凡在von Hippel-Lindau（VHL）疾病相关肿瘤中的应用：2期LITESPARK-004研究的5年随访
讲者：Vivek Narayan, MD, MS | Hospital of the University of Pennsylvania
摘要号：4508
英文标题：ALLO-316 in advanced clear cell renal cell carcinoma (ccRCC): Updated results from the phase 1 TRAVERSE study
中文标题：ALLO-316用于晚期透明细胞肾细胞癌（ccRCC）：1期TRAVERSE研究的更新结果
讲者：Samer Ali Srour, MBChB, MS | Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center
摘要号：5000
英文标题：Phase 3, randomized, placebo-controlled clinical trial of CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) for newly diagnosed localized prostate cancer
中文标题：CAN-2409+前药联合标准外照射放疗（EBRT）用于新诊断的局限性前列腺癌的3期、随机、安慰剂对照临床试验
讲者：Theodore L. DeWeese, MD | Johns Hopkins University School of Medicine
摘要号：5002
英文标题：Prognostic significance of PSA>0.2 after 6-12 months treatment for metastatic hormone-sensitive prostate cancer (mHSPC) intensified by androgen-receptor pathway inhibitors (ARPI): A multinational real-world analysis of the IRONMAN registry
中文标题：在使用雄激素受体通路抑制剂（ARPI）强化治疗的转移性激素敏感性前列腺癌（mHSPC）患者中，治疗6-12个月后PSA>0.2的预后意义：IRONMAN注册研究的多国真实世界分析
讲者：Michael Ong, MD, BSc, FRCPC | The Ottawa Hospital Cancer Centre
摘要号：5003
英文标题：Transcriptome classification of PTEN inactivation to predict survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for metastatic prostate cancer (PC): An ancillary study of the STAMPEDE trials
中文标题：通过转录组分类评估PTEN失活以预测在开始雄激素剥夺治疗（ADT）时从多西他赛中获益的生存优势，用于转移性前列腺癌（PC）：STAMPEDE试验的辅助研究
讲者：Emily Grist, PhD, BSc, MBBS, MRCP | University College London Cancer Institute
摘要号：5004
英文标题：Health-related quality of life (HRQoL) outcomes with darolutamide in the phase 3 ARANOTE trial
中文标题：在3期ARANOTE试验中，达罗他胺对健康相关生活质量（HRQoL）的影响
讲者：Alicia K. Morgans, MD, MPH, FASCO | Dana-Farber Cancer Institute
摘要号：5005
英文标题：ARCHES: 5-year follow-up overall survival (OS) analysis of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)
中文标题：ARCHES研究：恩扎卢胺（ENZA）联合雄激素剥夺治疗（ADT）用于转移性激素敏感性前列腺癌（mHSPC）患者的5年随访总生存（OS）分析
讲者：Andrew J. Armstrong, MD, MS | Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine
摘要号：LBA5006
英文标题：Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes
中文标题：3期AMPLITUDE试验：尼拉帕利（NIRA）联合醋酸阿比特龙加泼尼松（AAP）用于携带同源重组修复（HRR）基因改变的转移性去势敏感性前列腺癌（mCSPC）患者
讲者：Gerhardt Attard, MD, PhD | Cancer Institute, University College London
摘要号：5007
英文标题：A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): Initial efficacy and biomarker analysis
中文标题：一项多中心、随机、2期、研究者发起的ETCTN试验（COMRADE）：奥拉帕利+镭-223对比镭-223用于伴有骨转移（BM）的去势抵抗性前列腺癌（CRPC）男性患者：初步疗效和生物标志物分析
讲者：Rana R. McKay, MD, FASCO | University of California San Diego
摘要号：5008
英文标题：C3NIRA: Randomized phase II study of carboplatin-cabazitaxel-cetrelimab (anti-PD-1) induction followed by niraparib +/- cetrelimab maintenance in men with aggressive variant prostate cancers (AVPC)
中文标题：C3NIRA：一项随机2期研究，采用卡铂-卡巴他赛-cetrelimab（抗PD-1）诱导治疗，随后使用尼拉帕利±cetrelimab维持治疗用于患有侵袭性变异前列腺癌（AVPC）的男性患者
讲者：Ana Aparicio, MD | The University of Texas MD Anderson Cancer Center
口头摘要速递专场
（Rapid Oral Abstract Session）
摘要号：LBA4513
英文标题：ENLIGHTED phase 3 study: Interim results of efficacy and safety of padeliporfin vascular targeted photodynamic therapy (VTP) in the treatment of low-grade upper tract urothelial cancer (LG UTUC)
中文标题：ENLIGHTED 3期研究：帕利泊芬血管靶向光动力治疗（VTP）用于治疗低级别上尿路尿路上皮癌（LG UTUC）的疗效和安全性中期结果
讲者：Vitaly Margulis, MD | UT Southwestern Medical Center
摘要号：4514
英文标题：Five-year follow-up results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma (ccRCC)
中文标题：来自3期KEYNOTE-564研究的5年随访结果：帕博利珠单抗（pembro）作为辅助治疗用于透明细胞肾细胞癌（ccRCC）的治疗
讲者：Naomi Balzer Haas, MD | Abramson Cancer Center, University of Pennsylvania
摘要号：4515
英文标题：Zanzalintinib (zanza) + nivolumab (nivo) ± relatlimab (rela) in patients (pts) with previously untreated clear cell renal cell carcinoma (ccRCC): Results from an expansion cohort of the phase 1b STELLAR-002 study
中文标题：Zanzalintinib（zanza）联合纳武利尤单抗（nivo）±relatlimab（rela）用于既往未经治疗的透明细胞肾细胞癌（ccRCC）患者：1b期STELLAR-002研究的扩展队列结果
讲者：Jad Chahoud, MD, MPH, MHA | Moffitt Cancer Center
摘要号：4516
英文标题：Ipilimumab and nivolumab in patients with metastatic clear cell renal cell carcinoma (mccRCC) treated on the phase 3 PDIGREE (Alliance A031704) trial: Results from Step 1 analysis
中文标题：伊匹木单抗联合纳武利尤单抗用于接受3期PDIGREE（Alliance A031704）试验治疗的转移性透明细胞肾细胞癌（mccRCC）患者：第一步分析的结果
讲者：Tian Zhang, MD, MHS | Department of Internal Medicine, Division of Hematology and Oncology, UT Southwestern
摘要号：4517
英文标题：Sasanlimab in combination with bacillus Calmette-Guérin (BCG) in BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC): Event-free survival (EFS) subgroup analyses based on disease stage from the CREST study
中文标题：Sasanlimab联合卡介苗（BCG）用于BCG初治的高危非肌层浸润性膀胱癌（NMIBC）：基于疾病分期的无事件生存（EFS）亚组分析——来自CREST研究
讲者：Thomas Powles, MD, PhD, FCRP | Barts Cancer Centre, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London
摘要号：4518
英文标题：First results of SURE-02: A phase 2 study of neoadjuvant sacituzumab govitecan (SG) plus pembrolizumab (Pembro), followed by response-adapted bladder sparing and adjuvant pembro, in patients with muscle-invasive bladder cancer (MIBC)
中文标题：SURE-02研究的初步结果：一项2期研究，新辅助治疗使用Sacituzumab Govitecan（SG）联合帕博利珠单抗（pembro），随后根据应答情况进行膀胱保留治疗和辅助pembro治疗，用于肌层浸润性膀胱癌（MIBC）患者
讲者：Andrea Necchi, MD | IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University
摘要号：4519
英文标题：9MW2821, a novel Nectin-4 antibody-drug conjugate (ADC), combined with toripalimab in treatment-naïve patients with locally advanced or metastatic urothelial carcinoma (la/mUC): Results from a phase 1b/2 study
中文标题：9MW2821，一种新型Nectin-4抗体药物偶联物（ADC），联合特瑞普利单抗治疗未经治疗的局部晚期或转移性尿路上皮癌（la/mUC）患者：一项1b/2期研究结果
讲者：北京大学肿瘤医院 盛锡楠
摘要号：4520
英文标题：CLONEVO: Preoperative abemaciclib for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) with molecular response assessment
中文标题：CLONEVO：对于顺铂不耐受的肌层浸润性膀胱癌（MIBC）患者，术前使用阿贝西利，并进行分子缓解评估
讲者：Bishoy Morris Faltas, MD | Weill Cornell Medicine
摘要号：4521
英文标题：AREN1721, a randomized phase 2 trial of axitinib+nivolumab combination therapy vs. single agent nivolumab for the treatment of TFE/translocation renal cell carcinoma (tRCC) across all age groups, an NCI National Clinical Trials Network (NCTN) phase 2 study
中文标题：AREN1721：一项随机2期试验，比较阿昔替尼+纳武利尤单抗联合疗法与单药纳武利尤单抗治疗TFE/易位性肾细胞癌（tRCC）的疗效，涵盖所有年龄组——一项NCI国家临床试验网络（NCTN）2期研究
讲者：James I. Geller, MD | Cincinnati Children's Hospital Medical Center
摘要号：LBA5012
英文标题：An open label randomized non-inferiority trial comparing adjuvant platinum plus paclitaxel to platinum plus 5-FU after curative resection in high-risk penile carcinoma
中文标题：一项开放标签、随机、非劣效性试验，比较在高危阴茎癌根治性切除术后，辅助治疗中铂类联合紫杉醇与铂类联合5-FU的疗效
讲者：Aditya Dhanawat, MD, DM | Tata Memorial Centre
摘要号：5013
英文标题：Docetaxel with androgen deprivation therapy (ADT) and radiotherapy (RT) for high-risk localized prostate cancer (HRLPC): An ICECaP individual patient-data (IPD) meta-analysis of randomized controlled trials (RCTs)
中文标题：多西他赛联合雄激素剥夺治疗（ADT）和放疗（RT）用于高危局限性前列腺癌（HRLPC）：一项ICECaP个体患者数据（IPD）的随机对照试验（RCTs）荟萃分析
讲者：Praful Ravi, MBBChir, MRCP | Dana-Farber Cancer Institute
摘要号：5014
英文标题：Intensified hormonal blockade with SBRT in PSMA-PET detected oligometastatic prostate adenocarcinoma: Results from the phase II Metacure trial cohorts B2 and the B2 expansion
中文标题：在PSMA-PET检测到的寡转移性前列腺腺癌中，使用SBRT强化激素阻断：来自2期Metacure试验B2队列及B2扩展队列的结果
讲者：Eric Huttenlocher Bent, MD, PhD | Memorial Sloan-Kettering Cancer Center
摘要号：5015
英文标题：DB‑1311/BNT324 (a novel B7H3 ADC) in patients with heavily pretreated castrate-resistant prostate cancer (CRPC)
中文标题：DB-1311/BNT324（一种新型B7H3抗体偶联药物）用于接受过多次治疗的去势抵抗性前列腺癌（CRPC）患者
讲者：Andrew Ohyama Parsonson, FRACP, MBBS | Macquarie University
摘要号：5016
英文标题：177Lu-PSMA-617 with ipilimumab (ipi) and nivolumab (nivo) in metastatic castration-resistant prostate cancer (mCRPC): An investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001)
中文标题：177Lu-PSMA-617联合伊匹木单抗（ipi）和纳武利尤单抗（nivo）用于转移性去势抵抗性前列腺癌（mCRPC）：一项研究者发起的2期试验（EVOLUTION；ANZUP2001）
讲者：Shahneen Sandhu, MBBS, FRACP | Peter MacCallum Cancer Center and the University of Melbourne
摘要号：5017
英文标题：Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer (mCRPC)
中文标题：JNJ-78278343（pasritamig）在转移性去势抵抗性前列腺癌（mCRPC）中的1期研究结果
讲者：Capucine Baldini, MD, PhD | Drug Development Department (DITEP), Institut Gustave Roussy
摘要号：5018
英文标题：CA209-8TY trial, a randomized phase 2 trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in metastatic castration-resistant prostate cancer
中文标题：CA209-8TY试验：一项随机2期试验，纳武利尤单抗和伊匹木单抗联合或不联合立体定向体部放射治疗用于转移性去势抵抗性前列腺癌
讲者：Rikke Løvendahl Eefsen, MD, PhD | Department of Oncology, Experimental Cancer Therapy Unit
摘要号：5019
英文标题：Exploratory analyses of homologous recombination repair alterations (HRRm) by gene subgroup and potential associations with efficacy in the HRR-deficient population from TALAPRO-2
中文标题：在TALAPRO-2研究中，对同源重组修复改变（HRRm）按基因亚组进行的探索性分析及其与同源重组缺陷人群中疗效的潜在关联
讲者：Stefanie Zschaebitz, MD | National Center for Tumor Diseases (NCT)
摘要号：5020
英文标题：Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving 177Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603)
中文标题：在接受177Lu-PSMA-617或卡巴他赛治疗的转移性去势抵抗性前列腺癌（mCRPC）患者中进行的克隆性造血（CH）的探索性事后分析：一项随机2期试验（TheraP；ANZUP 1603）
讲者：Aslı Doğa Munzur, BSc | Vancouver Prostate Centre
临床科学研讨会
（Clinical Science Symposium）
摘要号：4509
英文标题：Exploratory analysis from NEOAVAX, a neoadjuvant trial of avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy
中文标题：来自NEOAVAX的探索性分析：一项新辅助试验，avelumab/阿昔替尼用于局部肾细胞癌（RCC）患者，这些患者在接受肾切除术后有高复发风险
讲者：Axel Bex, MD, PhD | Netherlands Cancer Institute
摘要号：4510
英文标题：Genomic characterization of baseline and post-progression tumors in IMmotion010, a randomized, phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with high-risk localized renal cell carcinoma (RCC)
中文标题：IMmotion010研究中基线和进展后肿瘤的基因特征分析：一项随机3期研究，比较辅助阿替利珠单抗（atezo）与安慰剂（pbo）用于高危局部肾细胞癌（RCC）患者
讲者：Sumanta Kumar Pal, MD, FASCO | Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center
摘要号：4511
英文标题：An integrative analysis of circulating and tumor microenvironment (TME) determinants of patient response in the Checkmate 9ER (CM 9ER) trial of nivolumab and cabozantinib (NIVO+CABO) in advanced renal cell carcinoma (aRCC)
中文标题：在CheckMate 9ER（CM 9ER）试验中，对纳武利尤单抗和卡博替尼（NIVO+CABO）用于晚期肾细胞癌（aRCC）患者的循环因素和肿瘤微环境（TME）决定因素进行的综合分析
讲者：David A. Braun, MD, PhD | Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine
摘要号：4512
英文标题：Gut-associated checkpoint as a prognostic biomarker in metastatic renal cell carcinoma (mRCC): Results from a randomized first-line clinical trial
中文标题：肠道相关检查点作为转移性肾细胞癌（mRCC）的预后生物标志物：来自一项随机一线临床试验的结果
讲者：Renee Maria Saliby, MD, MSc | Yale Cancer Center
摘要号：5009
英文标题：Lutetium-177-PSMA-617 in oligo-metastatic hormone sensitive prostate cancer (BULLSEYE trial)
中文标题：177镥Lu-PSMA-617用于寡转移性激素敏感性前列腺癌（BULLSEYE试验）
讲者：Bastiaan M. Privé, MD, PhD | Radboudumc
摘要号：5010
英文标题：First-in-human results of terbium-161[161Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET): A single-centre, single-arm, phase I/II study
中文标题：在转移性去势抵抗性前列腺癌患者中使用161Tb-Tb-PSMA-I&T放射性配体治疗的首次人体研究结果（VIOLET）：一项单中心、单臂、1/2期研究
讲者：James Patrick Buteau, MD | Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging; Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre; and Sir Peter MacCallum Department of Oncology, University of Melbourne
摘要号：5011
英文标题：Predictive and prognostic value of baseline PSMA-PET total tumor volume and SUV mean within ENZA-p, a randomized phase II trial of enzalutamide versus enzalutamide plus [177Lu] Lu-PSMA-617 (ANZUP1901)
中文标题：在ANZUP1901研究中，基线PSMA-PET总肿瘤体积和SUV平均值在ENZA-p中的预测和预后价值：一项随机2期试验，比较恩扎卢胺与恩扎卢胺联合[177Lu]Lu-PSMA-617
讲者：Louise Emmett, MD, FRACP, MBChB | Department of Theranostics and Nuclear Medicine, St Vincent's Hospital; Faculty of Medicine, UNSW
*本文根据目前官网信息整理汇总，如有疏漏，欢迎补充指正。
排版编辑：肿瘤资讯-Bear
苏公网安备32059002004080号
